Correction Bydureon Label

Correction Bydureon Label

Yesterday Diabetic Investor incorrectly reported that Bydureon was approved with a clean label stating – “Even better the approval came with NO BLACK BOX warnings which will give Amylin another advantage when competing against Novo Nordisk (NYSE:NVO) and their once-daily GLP-1 Victoza®” This statement is incorrect as Bydureon does have a black box warning over Thyroid Cancer.  This warning appears to be similar to the one issued when Victoza came to market.

Diabetic Investor regrets this error, although we were not the only new organization to miss this point as looking over the wide press coverage the approval has received there is barely any mention of this warning. We actually believe there are three reasons for this; first the black box warning was not mentioned in the company issued press release announcing the approval; second, there was no mention of the warning during the conference call and third just as this warning was no big deal for Victoza, it’s also no big deal for Bydureon. There is a fourth possibility that many of us were just too lazy and didn’t bother to read the Bydureon label.

The complete label can be found at www.Bydureon.com/PI.